10-Q quarterly report · filed Nov 3, 2026

Biomarin Pharmaceutical Inc (BMRN) Q3 2026 10-Q Quarterly Report

Short answer

Biomarin Pharmaceutical Inc (BMRN) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.0B (up 32.0% year over year) with net income of −$123M.

Q3 2026 key financials · XBRL

Revenue
$1.0B
+32.0% YoY · +3.5% QoQ
Net income
−$123M
−299.5% YoY · −374.4% QoQ
Operating margin
-8.0%
EPS (diluted)
−$0.63
−320.0% YoY · −373.9% QoQ

Source: XBRL data from the Biomarin Pharmaceutical Inc (BMRN) Q3 2026 10-Q on SEC EDGAR. USD.

Biomarin Pharmaceutical Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $1,024.6M, up $248.5M YoY from $776.1M
  • Gross margin 80.0% vs 81.9% YoY, pressured by lower-margin product mix
  • Best performer: GALAFOLD revenue $151.8M, worst: NAGLAZYME revenue $107.8M, down $14.2M YoY
  • Cash and investments $736.0M, down $1,316.8M from December 31, 2025; operating cash flow $577.0M
  • Near-term headwinds: inconsistent government orders, macroeconomic volatility, $70.0M BMN 450 upfront payment in fourth quarter, higher debt expense

Risk Factors

  • Acquisition integration risk: April 2026 Amicus and August 2026 Alesta acquisitions expanded operations and increased execution complexity
  • Liquidity risk: $736.0 million cash versus $4.2 billion debt, including 2027 Notes maturing in May 2027
  • Regulatory pricing risk: IRA Medicare negotiations, inflation rebates, and EU HTA regulation increase downward pricing pressure
  • Trade risk: 100% tariffs on certain patented pharmaceuticals and ingredients beginning September 29, 2026
  • Manufacturing risk: GALAFOLD and POMBILITI rely on single-source third-party manufacturers

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.